Introduction
During the course of providing additional analyses for the National Institute for Health and Care Excellence Technology Appraisal Committee, two errors were identified in the data entered in the network meta-analysis that informed the cost-effectiveness analysis described in the original report. 1 This corrigendum notice describes the errors identified and the impact of correcting these errors on the main analyses presented in the original report.
1

Description of the error identified
The number of hip fractures for patients receiving zoledronic acid in the Health Outcomes and Related Incidence with Zoledronic acid Once Yearly-Recurrent Fracture Trial (HORIZON- RFT) 2 had been incorrectly entered in the data sheet used for the network meta-analysis as 79, which was in fact the number of non-vertebral fractures, instead of 23. As this error had been introduced after the original data extraction sheet had been quality assured by a second reviewer, the other data used in the network meta-analysis for all four fracture outcomes were double-checked against the quality assured data extraction sheet. One other discrepancy was identified, which was that for the non-vertebral fracture outcome in the Fracture Intervention Trial (FIT) II, 3 the number at risk of vertebral fractures (n = 2077 for placebo and n = 2057 for alendronic acid) had been used instead of the number at risk of non-vertebral fractures (n = 2218 for placebo and n = 2214 for alendronic acid). Both of these errors were corrected and the network meta-analyses for hip fracture and non-vertebral fractures were re-run.
Corrected treatment effectiveness estimates
For the non-vertebral fracture outcome, the correction to the numbers at risk in the FIT II study had minimal impact on the efficacy, as can be seen in Table 1 . However, for the hip fracture outcome, the impact on the efficacy estimates was substatial, as can be seen in Table 1 . This was because in the original analysis the incorrect data inputted for the HORIZON-RFT study had estimated an increased rather than a decreased risk of hip fracture for zoledronic acid. This had affected the hazard ratio for zoledronic acid, but it had also affected the estimates of the hazard ratio for the other bisphosphonates as the network meta-analysis assumed a class effect.
Corrected base-case cost-effectiveness analyses
The results were re-run for the base-case scenario presented in the original publication using the corrected efficacy data shown in Table 1 . In the base-case scenario, the full data from the probablistic sensitivity analysis (PSA) for the whole population (2 million patients with one set of parameter samples per patient) were used to calculate average costs and quality-adjusted life-years (QALYs) for each of the 10 risk categories for both Qfracture and FRAX and an incremental analysis was conducted for each risk category. The original publication also explored the uncertainty around the base-case analysis by reporting cost-effectiveness acceptability curves for each risk category and structural sensitivity analyses using mid-point parameter estimates, but this corrigendum notice focuses only on the key base-case results.
The base-case results when estimating fracture risk using Qfracture and FRAX are summarised in Figures 1 and 2 , respectively (these replace Figures 89 and 102 in the original publication). Each point shows the mean incremental net benefit (INB) (relative to no treatment and when valuing a QALY at £20,000) and the mean 10-year absolute risk of fracture for one risk category for a particular bisphosphonate treatment.
A fully incremental analysis for each risk category is provided in Appendices 1 and 2 for QFracture and FRAX, respectively (these replace Appendices 9 and 10 in the original publication).
When using QFracture to estimate fracture risk, and valuing a QALY at £20,000, no treatment has the highest INB for patients in the first 3 risk categories (average risk scores of 0.5%, 0.7% and 1.0%, respectively). 10-year absolute risk of fracture (%) FIGURE 2 Incremental net benefit (when valuing a QALY at £20,000) compared with no treatment against the 10-year fracture risk from FRAX.
To estimate treatment thresholds for cost-effective intervention, the full data from the PSA for the whole population (2 million patients with one parameter sample per patient) were used in a non-parametric regression. The regression was used to estimate the relationship between INB and absolute fracture risk. The mean INB predicted by the regression across the range of risk scores represented in the simulated population are plotted in Figures 3 and 4 when estimating fracture risk using QFracture and FRAX respectively (these replace Figures 90 and 103 in the original publication). The results here differ from those presented in Figures 1 and 2 because non-parametric regression is able to average over the stochastic uncertainty associated with the individual patient trajectories while simultaneously estimating a smooth relationship between INB and absolute risk.
The risk level at which each treatment achieves a positive INB and the range over which each treatment is optimal (has a maximum INB based on the mean regression estimate) are summarised in Table 2 for QFracture and Table 3 for FRAX (these replace Tables 38 and 39, respectively).
It can be seen from Table 2 that for the revised analysis a strategy of no treatment with bisphosphonates is the optimal strategy (when valuing a QALY at £20,000) for patients with a QFracture score of < 1.2%. Alendronic acid is optimal from 1.2% to 20.8% and risedronic acid is optimal for patients with QFracture score of between 20.8% and 26.0%. In the original analysis, zoledronic acid was not optimal at any level of fracture risk but now it is optimal for QFracture scores of ≥ 26%. Oral and i.v. ibandronic acid are not optimal at any level of absolute fracture risk, but the INBs for oral ibandronic acid are close to those for the other oral bisphosphonates. In patients unable to take an oral medication, i.v. ibandronate would be optimal between 15.8% and 16.6% but i.v. zoledronate would be optimal > 16.6%. When using FRAX to predict absolute risk in the revised analysis (see Table 3 ), it can be seen that oral ibandronic acid is optimal for patients with a FRAX score of ≤ 2.5%, and alendronic acid is optimal treatment for patients with a risk level between 2.5% and 16.7%. Zoledronic acid is optimal for FRAX scores > 16.7%. In patients unable to take an oral medication, i.v. zoledronate would be optimal > 13.0% but i.v. ibandronic acid is never the optimal treatment. 
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